LINC02749: A Drug Target / Disease Biomarker (G100506082)

Target Name: LINC02749

NCBI ID: G100506082

LINC02749

Other Name(s): long intergenic non-protein coding RNA 2749 | Long intergenic non-protein coding RNA 2749

LINC02749: A Drug Target / Disease Biomarker

LINC02749 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is located in chromosome 6p21.3 and has been shown to be involved in a variety of cellular processes, including cell adhesion, migration, and invasion.

One of the most promising aspects of LINC02749 is its potential as a drug target. LINC02749 has been shown to be highly expressed in various tissues and has been linked to a number of diseases, including cancer. Additionally, studies have suggested that LINC02749 may be involved in the development of resistance to chemotherapy, which is a major issue in cancer treatment.

In addition to its potential as a drug target, LINC02749 has also been shown to be a potential biomarker. Studies have shown that LINC02749 is downregulated in various types of cancer, including breast, lung, and ovarian cancer. Additionally, LINC02749 has been shown to be associated with poor prognosis in cancer patients, which further supports its potential as a biomarker.

Another important aspect of LINC02749 is its expression pattern in various tissues. LINC02749 has been shown to be expressed in various tissues, including blood, fat, muscle, and tissue samples from cancer patients. Additionally, studies have shown that LINC02749 may be involved in the regulation of cellular processes, including cell adhesion and migration.

Overall, LINC02749 is a promising molecule with potential as a drug target and biomarker. Further studies are needed to fully understand its role in cancer and its potential as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 2749

The "LINC02749 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02749 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets